אדיזם  180  CD 이스라엘 - 히브리어 - Ministry of Health

אדיזם 180 cd

rafa laboratories ltd - diltiazem hydrochloride - קפסולות - שחרור מבוקר - diltiazem hydrochloride 180 mg - benzothiazepine derivatives - calcium channel blocker that is indicated for the treatment of hypertension and angina.

אדיזם 240  CD 이스라엘 - 히브리어 - Ministry of Health

אדיזם 240 cd

rafa laboratories ltd - diltiazem hydrochloride - קפסולות - שחרור מבוקר - diltiazem hydrochloride 240 mg - benzothiazepine derivatives - calcium channel blocker that is indicated for the treatment of hypertension and angina.

דפלפט תמיסה 이스라엘 - 히브리어 - Ministry of Health

דפלפט תמיסה

cts chemical industries ltd, israel - valproic acid as sodium - תמיסה (פומי) - valproic acid as sodium 200 mg/ml - valproic acid - treatment of generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.

טריטייס 1.25 מג 이스라엘 - 히브리어 - Ministry of Health

טריטייס 1.25 מג

sanofi israel ltd - ramipril - טבליה - ramipril 1.25 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

טריטייס 2.5 מג 이스라엘 - 히브리어 - Ministry of Health

טריטייס 2.5 מג

sanofi israel ltd - ramipril - טבליה - ramipril 2.5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

טריטייס 5 מג 이스라엘 - 히브리어 - Ministry of Health

טריטייס 5 מג

sanofi israel ltd - ramipril - טבליה - ramipril 5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.